Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected thai patients receiving indinavir boosted with ritonavir

Therapeutic Drug Monitoring

Volumn 33, Issue 1, 2011, Pages 25-31

  Cressey, Tim R ^a,b,c   Urien, Saik ^d,e,f   Hirt, Deborah ^d,e,f   Halue, Guttiga ^g   Techapornroong, Malee ^h   Bowonwatanuwong, Chureeratana ⁱ   Leenasirimakul, Prattana ^j   Treluyer, Jean Marc ^d,e,f   Jourdain, Gonzague ^a,b,c   Lallemant, Marc ^a,b,c  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Institut Cochin   (France)

^f Paris Descartes University   (France)

^g Phayao Provincial Hospital   (Thailand)

^h PRAPOKKLAO HOSPITAL   (Thailand)

ⁱ CHONBURI HOSPITAL   (Thailand)

^j NAKORNPING HOSPITAL   (Thailand)

more..

Author keywords

highly active antiretroviral therapy; HIV 1; indinavir; Thai patient population; therapeutic drug monitoring

Indexed keywords

INDINAVIR PLUS RITONAVIR;

ADULT; AGED; ALLOMETRY; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONTE CARLO METHOD; NEPHROTOXICITY; PRIORITY JOURNAL; THAILAND;

ADULT; BODY WEIGHT; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; MONTE CARLO METHOD; RITONAVIR; THAILAND; YOUNG ADULT;

EID: 78751655782     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182057f6f     Document Type: Article

References (23)

1. World Health Organization. Antiretroviral Therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Available at: http://www.who.int/hiv/pub/paediatric/ infants2010/en/index.html. 2010 Revision. Accessed July 1, 2010.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337:725-733.
3. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
4. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother. 1998;42:2784-2791. (Pubitemid 28501204)
5. Arnaiz JA, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS. 2003;17:831-840.
6. Boyd MA, Srasuebkul P, Khongphattanayothin M, et al. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antivir Ther. 2006;11:223-232.
7. Dieleman JP, Gyssens IC, van der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999;13:473-478.
8. Burger D, Boyd M, Duncombe C, et al. Pharmacokinetics and pharmacody-namics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother. 2003;51:1231-1238.
9. la Porte C, Back D, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Reviews in Antiviral Therapy. 2006;3:4-14.
10. Cressey TR, Leenasirimakul P, Jourdain G, et al. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J Antimicrob Chemother. 2005;55:1041-1044.
11. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 2004;48:3226-3232.
12. Cressey TR, Leenasirimakul P, Sukrakanchana P, et al. A Pharmacokinetic Study Comparing 600/100 IDV/RTV vs 400/100 IDV/RTV as Part of Highly Active Antiretroviral Therapy in HIV-Infected Thai Patients. XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
13. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit. 2003;25:393-399.
14. Savic RM, Jonker DM, Kerbusch T, et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodynam. 2007;34:711-726.
15. Zhou XJ, Sheiner LB, D'Aquila RT, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother. 1999;43:121-128.
16. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735-750.
17. Kappelhoff BS, Huitema AD, Sankatsing SU, et al. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol. 2005;60:276-286.
18. Bertrand J, Treluyer JM, Panhard X, et al. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol. 2009;65:667-678.
19. Lin JH, Chiba M, Chen IW, et al. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. Drug Metab Dispos. 1996;24: 1298-1306.
20. Burger DM, Siebers MC, Hugen PW, et al. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr. 2002;29:101-102.
21. Verstuyft C, Marcellin F, Morand-Joubert L, et al. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS. 2005;19: 2127-2131.
22. Crommentuyn KM, Kappelhoff BS, Mulder JW, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol. 2005;60:378-389.
23. Dickinson L, Boffito M, Back D, et al. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. J Antimicrob Chemother. 2009;63:1233-1243.